VRTX241213C450000
- 18.20
- -3.80-17.27%
Vertex Pharmaceuticals Newsroom
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $525
Jefferies follows JPMorgan's call on Vertex Pharmaceuticals (VRTX.US) and raises the target price to $550.
Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
Vertex Pharmaceuticals Analyst Ratings
Jefferies Upgrades Vertex Pharmaceuticals(VRTX.US) to Buy Rating, Raises Target Price to $550
Evercore ISI Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $506
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $570 From $560
Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $486
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Vertex Pharmaceuticals (VRTX) Receives a Hold From Stifel Nicolaus
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $490
Vertex Pharmaceuticals Analyst Ratings
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $575
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530
Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity
Vertex Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503